Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Army
UBS
Moodys
Fuji
Accenture
Fish and Richardson

Generated: August 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,238,053

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,238,053
Title:Methods for treatment of pain
Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
Inventor(s): Toll; Lawrence R. (Redwood City, CA), Yeomans; David C. (Sunnyvale, CA), Angst; Martin S. (Palo Alto, CA), Jacobs; Daniel I. (Mountain View, CA)
Assignee: Nocicepta LLC (Wilmington, DE)
Application Number:13/802,075
Patent Claims:1. A method for the treatment of pain comprising administering to an individual in need thereof an effective dose of a non-opioid peptide NOP agonist via intranasal administration, provided when the pain is a trigeminal nerve-associated pain, the non-opioid peptide NOP agonist is not co-administered with an oxytocin peptide.

2. The method of claim 1, wherein said treatment comprises treatment of a trigeminal pain, a somatic pain, a neuropathic pain or a visceral pain.

3. The method of claim 2, wherein said treatment comprises treatment of a somatic pain.

4. The method of claim 2, wherein said treatment comprises treatment of a neuropathic pain.

5. The method of claim 2, wherein said treatment comprises treatment of a visceral pain.

6. The method of claim 1, wherein said treatment comprises treatment of an acute pain or a chronic pain.

7. The method of claim 1, wherein the pain is a craniofacial pain or a head pain.

8. The method of claim 7, wherein the craniofacial pain or the head pain is caused by temporomandibular joint disorder (TMJ), migraine or trigeminal neuralgia.

9. The method of claim 8, wherein the craniofacial pain or the head pain is caused by temporomandibular joint disorder (TMJ).

10. The method of claim 8, wherein the craniofacial pain or the head pain is caused by migraine.

11. The method of claim 8, wherein the craniofacial pain or the head pain is caused by trigeminal neuralgia.

12. The method of claim 1, wherein said treatment comprises treatment of a somatic pain, a neuropathic pain or a visceral pain.

13. The method of claim 12, wherein the non-opioid peptide NOP agonist is not co-administered with an oxytocin peptide.

14. The method of claim 1, wherein the non-opioid peptide NOP agonist is selected from the group consisting of N/OFQ, truncated N/OFQ analogs, N/OFQ agonist peptides and NOP agonist hexapeptides.

15. The method of claim 14, wherein the non-opioid peptide NOP agonist is a truncated N/OFQ analog.

16. The method of claim 1, further comprising administering to the individual in need thereof at least one additional active agent, wherein the additional active agent is administered before, after or simultaneously with administration of the non-opioid peptide NOP agonist.

17. The method of claim 16, wherein the additional active agent is selected from the group consisting of non-peptide opioids, opioid and opioid-like peptides and their analogs, NMDA-receptor antagonists, sodium channel blockers, calcium channel blockers, adrenergic antagonists, gabaergic agonists, glycine agonists, cholinergic agonists, adrenergic agonists, epinephrine, anticonvulsants, Rho kinase inhibitors, PKC inhibitors, p38-MAP kinase inhibitors, ATP receptor blockers, endothelin receptor blockers, chemokines, interleukin and tumor necrosis factor blockers, pro-inflammatory cytokines, tricyclic antidepressants, serotonergic antagonists, serotonergic agonists, NSAIDs and COXIBs, acetaminophen, analgesic peptides, toxins, TRP channel agonists and antagonists, cannabanoids, antagonists of pro-nociceptive peptide neurotransmitter receptors CGRP1 and CGRP2, antagonists of pro-nociceptive peptide neurotransmitter receptor NK1, antagonists of pro-nociceptive peptide neurotransmitter receptor NK2, antagonists of pro-nociceptive peptide neurotransmitter receptor Y1-5, antagonists of pro-nociceptive peptide neurotransmitter receptors VPAC2, VPAC1 or PAC1, antagonists of pro-nociceptive peptide neurotransmitter receptors Gal1-3 or GalR1-3, agonists or antagonists of vasopressin, corticotropin releasing hormone (CRH), growth hormone releasing hormone (GHRH), luteinizing hormone releasing hormone (LHRH), somatostatin growth hormone release inhibiting hormone, thyrotropin releasing hormone (TRH), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), pancreatic polypeptide, peptide tyrosine-tyrosine, glucogen-like peptide-1 (GLP-1), peptide histidine isoleucine (PHI), pituitary adenylate cyclase activating peptide (PACAP), brain natriuretic peptide, cholecystokinin (CCK), islet amyloid polypeptide (IAPP) or amylin, melanin concentrating hormone (MCH), melanocortins (ACTH, .alpha.-MSH and others), neuropeptide FF (F8Fa), neurotensin, parathyroid hormone related protein, calcitonin, Agouti gene-related protein (AGRP), cocaine and amphetamine regulated transcript (CART)/peptide, 5-HT-moduline, hypocretins/orexins, nocistatin, prolactin releasing peptide, secretoneurin, urocortin and derivatives and analogues thereof.

18. The method of claim 1, wherein the non-opioid peptide NOP agonist is administered as a pharmaceutical composition.

19. The method of claim 18, wherein the pharmaceutical composition further comprises at least one additional active agent.

20. The method of claim 18, wherein the pharmaceutical composition further comprises one or more additional active agents selected from the group consisting of non-peptide opioids, opioid and opioid-like peptides and their analogs, NMDA-receptor antagonists, sodium channel blockers, calcium channel blockers, adrenergic antagonists, gabaergic agonists, glycine agonists, cholinergic agonists, adrenergic agonists, epinephrine, anticonvulsants, Rho kinase inhibitors, PKC inhibitors, p38-MAP kinase inhibitors, ATP receptor blockers, endothelin receptor blockers, chemokines, interleukin and tumor necrosis factor blockers, pro-inflammatory cytokines, tricyclic antidepressants, serotonergic antagonists, serotonergic agonists, NSAIDs and COXIBs, acetaminophen, analgesic peptides, toxins, TRP channel agonists and antagonists, cannabanoids, antagonists of pro-nociceptive peptide neurotransmitter receptors CGRP1 and CGRP2, antagonists of pro-nociceptive peptide neurotransmitter receptor NK1, antagonists of pro-nociceptive peptide neurotransmitter receptor NK2, antagonists of pro-nociceptive peptide neurotransmitter receptor Y1-5, antagonists of pro-nociceptive peptide neurotransmitter receptors VPAC2, VPAC1 or PAC1, antagonists of pro-nociceptive peptide neurotransmitter receptors Gal1-3 or GalR1-3, agonists or antagonists of vasopressin, corticotropin releasing hormone (CRH), growth hormone releasing hormone (GHRH), luteinizing hormone releasing hormone (LHRH), somatostatin growth hormone release inhibiting hormone, thyrotropin releasing hormone (TRH), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), pancreatic polypeptide, peptide tyrosine-tyrosine, glucogen-like peptide-1 (GLP-1), peptide histidine isoleucine (PHI), pituitary adenylate cyclase activating peptide (PACAP), brain natriuretic peptide, cholecystokinin (CCK), islet amyloid polypeptide (IAPP) or amylin, melanin concentrating hormone (MCH), melanocortins (ACTH, .alpha.-MSH and others), neuropeptide FF (F8Fa), neurotensin, parathyroid hormone related protein, calcitonin, Agouti gene-related protein (AGRP), cocaine and amphetamine regulated transcript (CART)/peptide, 5-HT-moduline, hypocretins/orexins, nocistatin, prolactin releasing peptide, secretoneurin, urocortin and derivatives and analogues thereof.

21. The method of claim 18, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, adjuvants, diluents or stabilizers.

22. The method of claim 18, wherein the pharmaceutical composition further comprises at least one protease inhibitor and/or at least one absorption enhancer.

23. The method of claim 18, wherein the non-opioid peptide NOP agonist is selected from the group consisting of N/OFQ, truncated N/OFQ analogs, N/OFQ agonist peptides and NOP agonist hexapeptides.

24. The method of claim 23, wherein the non-opioid peptide NOP agonist is a truncated N/OFQ analog.

25. The method of claim 1, wherein the non-opioid peptide NOP agonist is N/OFQ and the unit dose of the N/OFQ administered is about 0.2 mg to about 5000 mg.

26. The method of claim 1, wherein the administration results in reduction of a pain rating on the VAS of 30% or more.

Details for Patent 9,238,053

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Try a Free Trial Nocicepta LLC (Wilmington, DE) 2029-07-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Try a Free Trial Nocicepta LLC (Wilmington, DE) 2029-07-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Try a Free Trial Nocicepta LLC (Wilmington, DE) 2029-07-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Fuji
Mallinckrodt
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.